Jeffrey M. Shin

Array ( [id] => 20527305 [patent_doc_number] => 12545729 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Anti-TREM2 agonist antibodies and antigen-binding fragments thereof that can increase levels of soluble TREM2 in serum and brain tissue [patent_app_type] => utility [patent_app_number] => 19/252441 [patent_app_country] => US [patent_app_date] => 2025-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 51 [patent_no_of_words] => 14560 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19252441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20093436 [patent_doc_number] => 20250223372 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-10 [patent_title] => BISPECIFIC ANTI-HUMAN A-BETA/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 19/093136 [patent_app_country] => US [patent_app_date] => 2025-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19093136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20134919 [patent_doc_number] => 20250241963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-31 [patent_title] => PRODUCTION OF ENHANCED STEM CELL-BASED EXOSOMES AND USES IN SCAR TISSUE PREVENTION AND TREATMENT [patent_app_type] => utility [patent_app_number] => 19/065557 [patent_app_country] => US [patent_app_date] => 2025-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9717 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19065557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19848000 [patent_doc_number] => 20250093351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) [patent_app_type] => utility [patent_app_number] => 18/966342 [patent_app_country] => US [patent_app_date] => 2024-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9035 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18966342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19656995 [patent_doc_number] => 20240424060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES [patent_app_type] => utility [patent_app_number] => 18/763519 [patent_app_country] => US [patent_app_date] => 2024-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18763519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20016266 [patent_doc_number] => 20250154488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-15 [patent_title] => PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/759577 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 138970 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18759577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403654 [patent_doc_number] => 20240287165 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/611325 [patent_app_country] => US [patent_app_date] => 2024-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432546 [patent_doc_number] => 20240301044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/611374 [patent_app_country] => US [patent_app_date] => 2024-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297611 [patent_doc_number] => 20240226177 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => RETINAL PIGMENT EPITHELIAL CELL TRANSPLANTATION FOR THE TREATMENT OF CORNEAL ENDOTHELIAL DYSFUNCTION [patent_app_type] => utility [patent_app_number] => 18/592478 [patent_app_country] => US [patent_app_date] => 2024-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18592478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157741 [patent_doc_number] => 20240150448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => PAC1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/545688 [patent_app_country] => US [patent_app_date] => 2023-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18545688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050879 [patent_doc_number] => 20240092848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => WNT SIGNALING AGONIST MOLECULES [patent_app_type] => utility [patent_app_number] => 18/482736 [patent_app_country] => US [patent_app_date] => 2023-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 1438 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18482736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096424 [patent_doc_number] => 20240115651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => PEPTIDES FOR TREATING DISEASE AND REDUCING SYMPTOMS RELATED TO MULTIPLE SCLEROSIS [patent_app_type] => utility [patent_app_number] => 18/368431 [patent_app_country] => US [patent_app_date] => 2023-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17031 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18368431 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19815065 [patent_doc_number] => 20250073272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => PRODUCTION OF ENHANCED STEM CELL-BASED EXOSOMES AND USES IN SCAR TISSUE PREVENTION AND TREATMENT [patent_app_type] => utility [patent_app_number] => 18/240681 [patent_app_country] => US [patent_app_date] => 2023-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13965 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18240681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18901374 [patent_doc_number] => 20240016859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY [patent_app_type] => utility [patent_app_number] => 18/455205 [patent_app_country] => US [patent_app_date] => 2023-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13143 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18455205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20100271 [patent_doc_number] => 20250230207 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-17 [patent_title] => COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/447177 [patent_app_country] => US [patent_app_date] => 2023-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5916 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18447177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345251 [patent_doc_number] => 20240254214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab [patent_app_type] => utility [patent_app_number] => 18/360073 [patent_app_country] => US [patent_app_date] => 2023-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18360073 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18901367 [patent_doc_number] => 20240016852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => Application of Retinal Pigment Epithelial Cells as Corneal Endothelial Substitute [patent_app_type] => utility [patent_app_number] => 18/352690 [patent_app_country] => US [patent_app_date] => 2023-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18352690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18831083 [patent_doc_number] => 20230399608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => PROCESS FOR ESTABLISHING A HUMAN TESTICULAR TISSUE CULTURE SYSTEM [patent_app_type] => utility [patent_app_number] => 18/346691 [patent_app_country] => US [patent_app_date] => 2023-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29002 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 323 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18346691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018902 [patent_doc_number] => 20240075073 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => TREATING OPTIC NEURITIS WITH INDUCED PLURIPOTENT STEM CELL-DERIVED OLIGODENDROCYTE PRECURSOR CELLS [patent_app_type] => utility [patent_app_number] => 18/217160 [patent_app_country] => US [patent_app_date] => 2023-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10721 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18217160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879457 [patent_doc_number] => 20240002826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/340786 [patent_app_country] => US [patent_app_date] => 2023-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 146063 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18340786 [rel_patent_id] =>[rel_patent_doc_number] =>)